TY  - JOUR
AU  - Bonanad, Santiago
AU  - Teresa Alvarez, Maria
AU  - Nunez, Ramiro
AU  - Luis Poveda, Jose
AU  - Gil, Beatriz
AU  - Ruiz-Beato, Elena
AU  - Duran, Ana
AU  - Ivanova, Yoana
AU  - Perez-Roman, Ines
AU  - Gonzalez-Dominguez, Almudena
PY  - 2021
DO  - 10.33393/grhta.2021.2234
SN  - 2284-2403
UR  - https://hdl.handle.net/10668/27351
T2  - Global & regional health technology assessment
AB  - Introduction: Emicizumab is a first-in-class monoclonal antibody, recently authorized for the treatment of hemophilia A with inhibitors. This study aims to estimate the direct and indirect costs of the management of hemophilia A with inhibitors, in...
LA  - en
PB  - Aboutscience srl
KW  - Activated prothrombin complex concentrate
KW  - Costs
KW  - Emicizumab
KW  - Hemophilia A
KW  - Recombinant factor VIIa
KW  - Spanish consensus guidelines
KW  - Bypassing agents
KW  - Factor-viii
KW  - On-demand
KW  - Prophylaxis
KW  - Efficacy
KW  - Impact
TI  - Costs of the management of hemophilia A with inhibitors in Spain
TY  - research article
VL  - 8
ER  -